Related Experiment Video

Updated: Apr 18, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.8K

Delivery aspects of antioxidants in diabetes management

Lakshmi Sailaja Duvvuri1, Sameer Katiyar, Ashutosh Kumar

  • 1National Institute of Pharmaceutical Education and Research (NIPER), Department of Pharmaceutics , Hyderabad-500037 , India +91 40 23073741 ; +91 40 23073751 ; wahid@niperhyd.ac.in.

Expert Opinion on Drug Delivery
|January 14, 2015
PubMed
Abstract

Insights

Oxidative stress contributes to diabetic complications. While antioxidants show promise, their clinical use is limited by delivery challenges, necessitating advanced drug delivery systems for effective therapy.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Diabetology

Background:

  • Oxidative stress from reactive species is implicated in diabetic complications.
  • Dietary antioxidants offer a potential therapeutic strategy beyond oral antidiabetic drugs.
  • Current antioxidants face limitations like poor solubility, permeability, and degradation, hindering clinical efficacy.

Purpose of the Study:

  • To review the molecular mechanisms of oxidative stress in diabetic complications.
  • To discuss the challenges in translating antioxidant therapies to clinical practice.
  • To explore various drug delivery systems for enhancing antioxidant efficacy.

Main Methods:

  • Literature review of oxidative stress mechanisms in diabetes.
  • Analysis of limitations in current antioxidant drug delivery.
  • Exploration of conventional and novel drug delivery systems, including mitochondrial targeting.

Main Results:

  • Oxidative stress plays a key role in the initiation and progression of diabetic complications.
  • Significant hurdles exist in the clinical application of antioxidants due to their physicochemical properties and bioavailability.
  • Various drug delivery strategies are being investigated to overcome these limitations.

Conclusions:

  • Further clinical studies are needed to evaluate the long-term efficacy and safety of antioxidants.
  • Successful clinical application requires optimized drug delivery carriers, considering degradation, cellular uptake, and targeted delivery.
  • Robust preclinical and clinical trials are essential for designing effective antioxidant dosing and administration regimens.
Keywords:
antioxidantsdiabetesmitochondrial targetingnovel delivery systemsoxidative stress

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.3K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
999
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
8
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
921